SUPPLEMENTARY DATA Incretin-based therapies and the short-term risk of pancreatic cancer: results from two retrospective cohort studies Running title: Incretins and pancreatic cancer Mathieu Boniol 1,2 , Matteo Franchi 3, Maria Bota 1,2 , Agnès Leclercq 4, Joeri Guillaume 4, Nancy van Damme 5, Giovanni Corrao 3, Philippe Autier, 1,2 Peter Boyle 1,2 1 International Prevention Research Institute (iPRI), Lyon (France) 2. Strathclyde Institute for Global Public Health at iPRI, Lyon (France) 3 Laboratory of Healthcare Research and Pharmacoepidemiology, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan (Italy) 4. Intermutualistic Agency (AIM-IMA), Brussels (Belgium) 5 Belgian Cancer Registry, Brussels (Belgium) Correspondence to : Philippe Autier, MD, International Prevention Research Institute (iPRI) , 95, Cours Lafayette, 69006 Lyon (France); E-mail: [email protected]; www.i-pri.org Supplementary Table S1. Selection of subjects for inclusion in the retrospective cohorts Belgium Lombardy Region (2008-2013) (2008-2012) Subjects 18 years old and more with 1 new prescription of a NIAD or of an incretin* 407,623 215,495 Subjects with insulin as first anti-diabetic therapy 38,298 24,261 Subjects with abnormal death delays and abnormal follow-up times 648 863 Subjects prescribed with lixisenatide 23 0 Subjects in the retrospective cohort, for analysis 368,654 190,371 Ever used a NIAD but not an incretin 345,672 180,061 Ever used an incretin 22,982 10,310 Ever used a DPP4i and not a GLP -1 RA 20,019 7,997 Ever used a GLP-1 RA and not a DPP4i 2,004 1,958 Ever used a DPP4i and a GLP-1 RA 959 355 * From 01/07/2008 in Belgium and from 01/01/2008 in the Lombardy Region ©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-0280/-/DC1 SUPPLEMENTARY DATA Supplementary Table S2. Time to insulin prescription in subjects taking a non-insulin, non-incretin anti-diabetic therapy Belgium Lombardy Region P- P- Non PaCa PaCa * Non PaCa PaCa * value value Number of subjects with a prescription 38,533 518 8,341 328 of insulin Median time (Q1- Q3) from first NIAD to first insulin 440 (110-909) 319 (92-701) <0·001 307 (47-770) 271 (96-587) 0·76 prescription (in days) Number of subjects with a prescription 22,190 55 9,509 28 of incretin Median time (IQR) from first NIAD to first incretin 595 (201-1042) 333 (111-875) 0·026 529 (119-979) 53 (0-605) <0·001 prescription (in days) NIAD: non-insulin, non-incretin anti-diabetic therapy; PaCa: pancreatic cancer * Two-sided Wilcoxon Two-Sample Test ©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-0280/-/DC1 .